Bret Hulick was in his second year of medical school at LECOM in Erie, analyzing the case of a 24-year-old colon cancer ...

Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose administration for the first patient in a Phase 2 trial for its experimental drug ...

Our colorectal trial, supported by F ... in a Phase 1b/2 trial combining LIXTE's LB-100 with GSK's immunotherapy, dostarlimab-gxly, targeting ovarian clear cell carcinoma. Dosing of the first ...

The first patient dosing in a Phase 1b/2 trial combining LIXTE's LB-100 with GSK's immunotherapy, dostarlimab-gxly ... ("Roche”) for treatment of unresponsive (MSI Low) metastatic colorectal cancer.

Dostarlimab is a checkpoint inhibitor that ... They also highlight MSK's unique expertise in treating young-onset colorectal cancers through its specialized Center for Young Onset Colorectal ...

Our colorectal trial, supported by F ... The first patient dosing in a Phase 1b/2 trial combining LIXTE's LB-100 with GSK's immunotherapy, dostarlimab-gxly, targeting ovarian clear cell carcinoma.

Pre-Clinical Study in Collaboration with Netherlands Cancer Instituteis in addition to LIXTE’s Ongoing Clinical Trials for Ovarian and Colorectal Cancers PASADENA, Calif., March 31, 2025 (GLOBE ...